Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$2.47 USD
+0.05 (2.07%)
Updated Aug 15, 2024 11:43 AM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACST 2.47 +0.05(2.07%)
Will ACST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACST
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
ACST: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
TEVA to Pay $250 Million to Settle Price-Fixing Charges
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
Other News for ACST
Craig-Hallum Issues a Buy Rating on Acasti Pharma (ACST)
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Acasti Pharma GAAP EPS of -$0.24
Acasti Pharma sees cash runway into 2Q26
Acasti Pharma reports Q1 EPS (24c) vs. (54c) last year